Antisense modulation of Toll-like receptor 4 expression
Source: Expert Opinion on Therapeutic Patents, Volume 13, Number 12, 1 December 2003 , pp. 1887-1889(3)
Publisher: Informa Healthcare
Abstract:A strategy to decrease the expression of Toll-like receptor 4 (TLR4) using antisense oligonucleotides is claimed. TLR4 has been implicated in sepsis syndrome and in chronic inflammatory diseases such as inflammatory bowel disease. Limiting TLR4 expression by the strategy described in the claim may therefore have clinical utility in these diseases.
Document Type: Miscellaneous
Publication date: December 1, 2003